To block non-specific binding, sections were treated with 4% BSA for 30 minutes.
To avoid nonspecific binding, slides were treated with 1% normal goat serum for 15 min followed by incubation with the rat-anti-mouse perforin mAb (Alexis, Grünberg, Germany) for 45 min.
At the end of the binding, cells were treated with or without the membrane-impermeable chemical amine-reactive cross-linking agent DTSSP (3,3'-dithiobis [sulfosuccinimidylpropionate] (Pierce Biotechnology Inc., Rockford, IL, USA) at 1 mM for 30 minutes.
To block non-specific protein binding, sections were treated with 3% normal goat serum and 0.05% Tween-20 (Biorad; Hercules, CA) in 1x APK buffer (Ventana Medical Systems, Inc.; Tucson, AZ) for 20 minutes at ambient temperature.
In order to show if the above effect was mediated by HMGB1-RAGE binding, cells were treated with anti-RAGE antibody and then stimulated with HMGB1 for 24 h. Figure 2 shows that when RAGE is blocked by anti-RAGE, the presence of HMGB1 does not significantly increase miR221 and miR222 expression in both CAL62 cells and BCPAP.
For detection of CFH-binding cells were treated with purified human CFH for 1 h at RT followed by incubation with CFH-specific mAb JHD7.
To determine if iAs affects GR/GRE binding, 1470.2 cells were treated with 5 nM Dex±8 µM iAs for 15, 30, 60, 120, or 180 min. Chromatin immunoprecipitation (ChIP) analysis was done to determine GR association with the MMTV promoter on nucleosome B (NucB) that has 4 GREs.
To avoid the heparin's interfering for binding, plasma samples were treated with heparinase I before testing.
To block nonspecific binding, the sections were treated with 3% donkey serum in TBS with 0.1% Triton X-100 for 30 min (Jackson Immunoresearch Laboratories Inc, West Grove, PA, USA).
After incubation in 1 10 diluted Flebogamma (Instituto Grifols) to block nonspecific binding sites, cells were treated with 1 mg/ml IgG as indicated.
